BioCardia (BCDA) Stock Price
BioCardia Price
Revenue at BioCardia has contracted by 13.2% per year over the past 17 years to 58,000.00 USD. Earnings per share have declined at 69.7% per year over the last 4 years. BioCardia's net margin stands at -13,700.0%, down from -10,347.6% several years earlier. Analysts set a median price target of 25.50 USD, implying 2,239.4% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 42% above its 52-week low.
BioCardia stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of BioCardia over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioCardia stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioCardia's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | BioCardia Price |
|---|---|
| 9/3/2026 | 1.09 USD |
| 9/2/2026 | 1.11 USD |
| 9/1/2026 | 1.10 USD |
| 8/31/2026 | 1.14 USD |
| 8/28/2026 | 1.15 USD |
| 8/27/2026 | 1.17 USD |
| 8/26/2026 | 1.19 USD |
| 8/25/2026 | 1.13 USD |
| 8/24/2026 | 1.01 USD |
| 8/21/2026 | 1.01 USD |
| 8/20/2026 | 0.97 USD |
| 8/19/2026 | 0.99 USD |
| 8/18/2026 | 0.94 USD |
| 8/17/2026 | 0.94 USD |
| 8/14/2026 | 0.97 USD |
| 8/13/2026 | 0.93 USD |
| 8/12/2026 | 0.91 USD |
| 8/11/2026 | 0.93 USD |
| 8/10/2026 | 0.97 USD |
| 8/7/2026 | 0.98 USD |
| 8/6/2026 | 0.95 USD |
| 8/5/2026 | 0.97 USD |
| 8/4/2026 | 0.91 USD |
| 8/3/2026 | 0.83 USD |
| 7/31/2026 | 0.82 USD |
| 7/30/2026 | 0.77 USD |
| 7/29/2026 | 0.78 USD |
| 7/27/2026 | 0.86 USD |
| 7/23/2026 | 0.91 USD |
| 7/22/2026 | 0.91 USD |
BioCardia Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
BioCardia Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | 1.00 | 1.00 | – | – | – | – | – | 4.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| – | – | – | – | – | – | – | – | -400.00 | -1,000.00 | – | – | – | – | – | -100.00 |
| -4.00 | -4.00 | -4.00 | -4.00 | -4.00 | -4.00 | -4.00 | -4.00 | -4.00 | -10.00 | -7.00 | -4.00 | -4.00 | -4.00 | -4.00 | -4.00 |
| – | – | – | -7.00 | -12.00 | -14.00 | -14.00 | -15.00 | -12.00 | -11.00 | -11.00 | -8.00 | -8.00 | -4.00 | -3.00 | -2.00 |
| – | – | – | – | – | – | – | – | -1,200.00 | -1,100.00 | – | – | – | – | – | -50.00 |
| – | – | – | -10.00 | -12.00 | -13.00 | -14.00 | -15.00 | -12.00 | -11.00 | -11.00 | -7.00 | -8.00 | -6.00 | -5.00 | -4.00 |
| – | – | – | – | 20.00 | 8.33 | 7.69 | 7.14 | -20.00 | -8.33 | – | -36.36 | 14.29 | -25.00 | -16.67 | -20.00 |
| 0.01 | 0.01 | 0.04 | 0.04 | 4.25 | 4.85 | 6.83 | 0.89 | 1.14 | 1.22 | 1.50 | 2.74 | 10.76 | 10.76 | 10.76 | 10.76 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales BioCardia generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioCardia retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioCardia's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares BioCardia has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioCardia's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
BioCardia stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
BioCardia Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
BioCardia business model & stock analysis
BioCardia Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
BioCardia Segments
BioCardia Revenue by Segment
3 Years
5 Years
Max
Details
BioCardia Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
BioCardia historical P/E ratio, EBIT multiple, and P/S ratio
BioCardia annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
BioCardia shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
BioCardia stock splits
Current BioCardia forecasts and price targets in September 2026
Analyst Price Targets 2026BioCardia Analyst Rating Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| 6/9/2026 | Maintained | Buy | |
| 9/22/2025 | Maintained | Buy | |
| 12/18/2024 | Maintained | Buy | |
| 11/14/2024 | Maintained | Buy | |
| 10/28/2024 | Maintained | Buy | |
| 8/21/2024 | Maintained | Buy | |
| 8/16/2024 | Maintained | Buy | |
| 7/26/2024 | Maintained | Buy | |
| 5/29/2024 | Maintained | Buy | |
| 11/14/2023 | Maintained | Buy |
BioCardia Earnings Calls
BioCardia Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/12/2026 | -0.18USD | - | 0.00USD | - | 2026 Q2 |
| 5/15/2026 | -0.17USD | - | 0.00USD | - | 2026 Q1 |
| 4/1/2026 | -0.17USD | - | 0.00USD | - | 2025 Q4 |
| 11/13/2024 | -1.21USD | - | 204,000.00USD | - | 2024 Q3 |
| 5/8/2024 | -0.20USD | - | -USD | - | 2024 Q1 |
| 3/27/2024 | -0.10USD | - | 193,800.00USD | - | 2023 Q4 |
| 8/8/2023 | -0.19USD | - | -USD | - | 2023 Q2 |
| 5/9/2023 | -0.21USD | - | -USD | - | 2023 Q1 |
| 3/27/2023 | -0.21USD | - | 103,529.00USD | - | 2022 Q4 |
| 11/9/2022 | -0.23USD | - | 76,459.00USD | - | 2022 Q3 |
BioCardia shareholder structure
| % | Name |
|---|---|
7.54006% | |
3.16680% | |
2.06033% | |
1.22526% | |
0.45193% | |
0.36577% |
BioCardia Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
65.00% | SEC ↗ | |
65.00% | SEC ↗ | |
32.70% | SEC ↗ | |
32.70% | SEC ↗ | |
9.90% | SEC ↗ | |
8.60% | SEC ↗ | |
8.50% | SEC ↗ | |
7.54% | SEC ↗ | |
6.30% | SEC ↗ | |
5.80% | SEC ↗ |
BioCardia Executives and Management Board
9 members · avg. age 68 · 0 % women
Dr. Peter Altman (57)
President, Chief Executive Officer, Director · since 2002
746,237.00 USD
Management
Mr. David Mcclung (60)
Chief Financial Officer
Mr. Edward Gillis (62)
Senior Vice President - Devices
Board of Directors
Mr. Andrew Blank (68)
Independent Chairman of the Board
Mr. Jay Moyes (70)
Independent Director
Dr. Richard Krasno (82)
Independent Director
Mr. Jim Allen (68)
Independent Director
Dr. Simon Stertzer (88)
Independent Director
Mr. Bill Facteau (54)
Independent Director
Frequently asked questions about BioCardia
Analysts currently set an average price target of 25.50 USD for the BioCardia stock (median: 25.50 USD), implying +2,261.1 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the BioCardia stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BioCardia to generate revenue of 50,000.00 USD and earnings per share of -0.62 USD.
Converted at the current exchange rate, the BioCardia share trades at 0.94 EUR (1.09 USD).
The BioCardia share (BCDA) is listed on 3 stock exchanges, including: NASDAQ (BCDA), Frankfurt (6JU.F), München (6JU.MU).
No history available for BioCardia.
The expected revenue of BioCardia is 50,000.00 USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BioCardia is -6.68 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BioCardia is currently -1.75. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioCardia stock.
The price-to-sales ratio (P/S) of BioCardia is currently 234.47. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioCardia stock.
The Eulerpool Quality Score for BioCardia is 2/10.
The ISIN of BioCardia is US09060U6064. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BioCardia is A2PLXH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BioCardia is BCDA. The ticker symbol is used to trade BioCardia shares on the stock exchange.
BioCardia paid dividends every year for the past 0 years.
BioCardia is assigned to the 'Health' sector.
The dividends of BioCardia are distributed in USD.
BioCardia stock
BioCardia Peer Group
BioCardia Ticker
All fundamentals and in-depth analysis of BioCardia
Our stock analysis for BioCardia stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioCardia. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.